News Chart Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 23:00:00 02/09/2026 +03			5-day change	1st Jan Change
14.22 ^USD	-0.63%		-2.34%	-9.31%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

fa728eed.JwNMyz11FQHnBHGzNkYJLTVor_4iE50FV0C6xe0UB6I.XjEAsnkEY2aoTRLkegNDQEJe6K5WPq1jIC7JjIFFN9J0Qi_4ZSYnZ7QzBg~308914a47fc4d081fa542b3cdafbc3eb